Spero Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Spero Therapeutics, Inc.‘s stocks are currently a part of 27 hedge funds’ portfolios, which represents 13.56% of the total amount of its stocks outstanding. This makes up a total of 5.09M shares of Spero Therapeutics, Inc.. Compared to the previous quarter, the number fell by -64.16% or -9.12M shares fewer. As for the holding position changes, 33.33% (9) of current hedge fund investors increased the number of shares held, 11.11% (3) of current holders sold a part of the shares held, and 25.93% (7) closed the holdings completely. 1 hedge funds are new holders of Spero Therapeutics, Inc. stock in Q1 2023, it is 3.7% of total holders.
Hedge funds holding Spero Therapeutics (Q2 2018 – Q1 2023)
| Q2 2018 | 44 |
|---|---|
| Q3 2018 | 51 |
| Q4 2018 | 50 |
| Q1 2019 | 53 |
| Q2 2019 | 59 |
| Q3 2019 | 58 |
| Q4 2019 | 60 |
| Q1 2020 | 59 |
| Q2 2020 | 78 |
| Q3 2020 | 75 |
| Q4 2020 | 86 |
| Q1 2021 | 90 |
| Q2 2021 | 86 |
| Q3 2021 | 86 |
| Q4 2021 | 82 |
| Q1 2022 | 96 |
| Q2 2022 | 64 |
| Q3 2022 | 60 |
| Q4 2022 | 55 |
| Q1 2023 | 27 |
Hedge funds changes in Spero Therapeutics positions (Q2 2018 – Q1 2023)
| Q2 2018 | 13 | 13 | 7 | 3 | 8 |
|---|---|---|---|---|---|
| Q3 2018 | 13 | 24 | 5 | 6 | 3 |
| Q4 2018 | 10 | 16 | 13 | 11 | 0 |
| Q1 2019 | 10 | 15 | 16 | 7 | 5 |
| Q2 2019 | 9 | 24 | 10 | 3 | 13 |
| Q3 2019 | 6 | 27 | 12 | 7 | 6 |
| Q4 2019 | 8 | 28 | 11 | 6 | 7 |
| Q1 2020 | 7 | 30 | 15 | 7 | 0 |
| Q2 2020 | 27 | 34 | 12 | 8 | -3 |
| Q3 2020 | 11 | 30 | 21 | 14 | -1 |
| Q4 2020 | 24 | 33 | 23 | 14 | -8 |
| Q1 2021 | 14 | 27 | 26 | 8 | 15 |
| Q2 2021 | 15 | 28 | 21 | 19 | 3 |
| Q3 2021 | 6 | 22 | 26 | 6 | 26 |
| Q4 2021 | 9 | 25 | 20 | 13 | 15 |
| Q1 2022 | 25 | 15 | 22 | 10 | 24 |
| Q2 2022 | 14 | 19 | 18 | 44 | -31 |
| Q3 2022 | 15 | 10 | 19 | 19 | -3 |
| Q4 2022 | 17 | 10 | 15 | 22 | -9 |
| Q1 2023 | 1 | 9 | 3 | 7 | 7 |
Hedge funds changes in Spero Therapeutics stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 0 | 0 |
|---|---|---|
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 1,000 | 1,000 |
| Q2 2019 | 0 | 1,000 |
| Q3 2019 | 0 | 1,000 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 19,000 | 0 |
| Q3 2020 | 217,000 | 614,000 |
| Q4 2020 | 1,500,000 | 2,039,000 |
| Q1 2021 | 889,000 | 1,579,000 |
| Q2 2021 | 1,309,000 | 711,000 |
| Q3 2021 | 2,005,000 | 1,210,000 |
| Q4 2021 | 1,096,000 | 711,000 |
| Q1 2022 | 219,000 | 15,000 |
| Q2 2022 | 36,000 | 34,000 |
| Q3 2022 | 241,000 | 919,000 |
| Q4 2022 | 381,977 | 226,093 |
| Q1 2023 | 9,590,000 | 145,000,000 |